Risk Benefit Analysis

KEY POINTS
These are not classical vaccines. These are gene therapy products whose long term consequences are unknown. FDA have not followed their own guidelines in this matter.

• A number of important safety studies in animals that would be expected have not been done (cancer, genotoxicity, studies in juvenile animals)

• Pfizer's quasi vaccine data for children has not been verified by FDA . Many statistical issues cast doubt on Pfizer's estimate of 91% efficacy.

• Pfizer have changed the formulation from the one that was tested, without any further safety of (see)

• FDA 's risk-benefit analysis (comparing no vax vs. full vax) for children is off by 26 times to give (conservatively) a 4x RISK more than benefit. Several new factors modify this:

  • - lowered benefit of vaccine against omicron (unknown, but assume only (50%)

  • - even assuming lower risks of myocarditis based on recent CDC numbers (which appar flawed) STILL gives a higher RISK.

• Why limit contraindication to Janssen? Using same criteria revisit EUA/BLA for all C19 quasi-vaccines. Transparency: Emergency ACIP Meeting Dec 16 2021: A second open letter to Dr. Grace Lee, ACIP Chair

• This video goes through the Pfizer 6-month data shows that Pfizer’s COVID-19 inoculations cause more illness than they prevent. Plus, an overview of the Pfizer trial flaws in both design and execution.

• The Canadian Covid Care Alliance Power Point Presentation